化学性质：                                                                                                             

产品描述：                                                                                                            

TRV130 is a novel mu opioid receptor (MOR) agonist that preferentially activates G-protein versus β-arrestin signaling pathways coupled to MORs.

In cell-based assays, TRV130 elicits robust G protein signaling, with potency and efficacy similar to morphine, but with far less β-arrestin recruitment and receptor internalization[2].

TRV130 treatment produces robust antinociception, complete inhibition of gastrointestinal function, and weak abuse-related effects in mice[1]. TRV130 displays an ED50 of 0.9 mg/kg in an analgesic assay. TRV130 analgesia is reversible in mice by administration of 3 mg/kg naloxone s.c. 15 minutes after TRV130 dosing. In the rat 52°C hot plate, TRV130 is 10-fold more potent than morphine with ED50 of 0.32 and 3.2 mg/kg, respectively. TRV130 (0.3 mg/kg, s.c.) possesses an improved therapeutic index of analgesia to constipation relative to morphine in mice[2]. TRV130 (1.2 mg/kg, s.c.) significantly depresses respiration of mice[3].

特别提醒：